ArticleInfectious diseases in obstetrics and gynecology2008
The metabolism and transplacental transfer of oseltamivir in the ex vivo human model.
Article in Infectious diseases in obstetrics and gynecology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 43 citations in OpenAlex.
- Clinical Effectiveness and Safety of Antivirals for Influenza in Pregnancy.Open forum infectious diseases · 2021Review
- HPLC Method for Quantification of Caffeine and Its Three Major Metabolites in Human Plasma Using Fetal Bovine Serum Matrix to Evaluate Prenatal Drug Exposure.Journal of analytical methods in chemistry · 2018Article
- Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study.BMJ (Clinical research ed.) · 2017Observational
- Oseltamivir for influenza in pregnancy.Seminars in perinatology · 2014Review
- The placenta in toxicology. Part IV: Battery of toxicological test systems based on human placenta.Toxicologic pathology · 2014Review
- Influenza in pregnancy.Influenza and other respiratory viruses · 2013Review
- Clinical use of approved influenza antivirals: therapy and prophylaxis.Influenza and other respiratory viruses · 2013Review
- Transplacental transfer of oseltamivir carboxylate.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2012Article
- Chemical analysis and transplacental transfer of oseltamivir and oseltamivir carboxylic acid in pregnant rats.PloS one · 2012Article
- Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.Advances in therapy · 2011Review
- Pharmacokinetics of oseltamivir according to trimester of pregnancy.American journal of obstetrics and gynecology · 2011Article
- Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.Clinical pharmacokinetics · 2010Review
- Review
- Antiviral medications for pregnant women for pandemic and seasonal influenza: an economic computer model.Obstetrics and gynecology · 2009Article
- Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2009Review
- H1N1 Influenza in Pregnancy: What All Obstetric Care Providers Ought to Know.Reviews in obstetrics & gynecology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledOseltamivir phosphate is extensively metabolized in the ex vivo human placenta model, and the transplacental passage of the metabolite oseltamivir carboxylate is incomplete.
objectiveTo evaluate the metabolism and transplacental transfer of oseltamivir (Tamiflu) in the ex vivo human placental model. STUDY
designPerfusion studies were performed in six placentas from term, uncomplicated deliveries. Concentrations of oseltamivir phosphate (OP) that were 5-6 fold, 20-30 fold, and 600-800 fold above the therapeutic peak were tested, as neither OP nor its active metabolite, oseltamivir carboxylate (OC), could be detected at near-therapeutic concentrations. The transplacental transfer and accumulation of OC were assessed using the (14)C antipyrine reference method.
resultsOP was extensively metabolized to OC. In the 4 placentas with the highest concentration of OP, OC had a mean clearance index of 0.13 +/- 0.08, suggesting that transplacental passage occurs at a relatively low rate. Measurable fetal accumulation occurred in the two placentas with the highest initial concentrations.
conclusionsOseltamivir phosphate was extensively metabolized in the ex vivo model. Transplacental transfer of the metabolite was incomplete and accumulation was minimal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.